CStone Reports CS2009 Clinical Data From More Than 300 Patients
CStone says data from more than 300 patients support CS2009’s mechanism, safety and broad antitumor activity. The company describes CS2009 as a PD-1/VEGF/CTLA-4 trispecific antibody.
CStone says data from more than 300 patients support CS2009’s mechanism, safety and broad antitumor activity. The company describes CS2009 as a PD-1/VEGF/CTLA-4 trispecific antibody.